Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

1.350 +0.040 (+3.05%)
Streaming Delayed Price Updated: 10:09 AM EDT, Jun 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pliant Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
From Aligos Therapeutics
Via GlobeNewswire
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Events
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Events
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Events
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Conferences
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Events
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
INTEGRIS-PSC interim results highlighted in an oral late-breaker presentation 
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Conferences
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
Interim results from INTEGRIS-PSC to be featured in an oral presentation on Monday, November 13 
From Pliant Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.